Advaxis (ADXS) has risen sharply, recording gains of 74.2% in the past 4 weeks. However, the stock has corrected -0.56% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 72.42% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 36.35% and the 50-Day Moving Average is 53.6%. Advaxis (NASDAQ:ADXS): stock turned positive on Friday. Though the stock opened at $14.2, the bulls momentum made the stock top out at $14.8 level for the day. The stock recorded a low of $14.057 and closed the trading day at $14.18, in the green by 0.21%. The total traded volume for the day was 1,026,836. The stock had closed at $14.15 in the previous days trading.
The company Insiders own 4.56% of Advaxis shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -30.16% . Institutional Investors own 60.95% of Advaxis shares. During last six month period, the net percent change held by insiders has seen a change of -12%. Also, Equity analysts at the Brokerage firm Barclays maintains its rating on Advaxis (NASDAQ:ADXS). The rating major has initiated the coverage with overweight rating on the shares. The Analysts at Barclays raises the price target from $15 per share to $20 per share. The rating by the firm was issued on August 3, 2016.
Advaxis, Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on developing various cancer immunotherapies that use the bodys natural immune system to redirect the immune response to kill cancer. Its Lm Technology is a cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen, and neutralizes regulatory T cells and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Its Lm Technology immunotherapy, axalimogene filolisbac (ADXS-HPV), targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase II in invasive cervical cancer, Phase I/II in head and neck cancer, and Phase I/II in anal cancer. It has preclinical program with immunotherapies in development for cancers and infectious diseases.